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Principles of Research Tissue Banking and Specimen
Evaluation from the Pathologist’s Perspective
Sandra A. McDonald
Human tissue biorepositories have an increasingly visible and important role within industrial enterprises in
supporting biomedical research, including the rapidly advancing fields of proteomics, pharmacogenomics, and
molecular epidemiology. Pathologists play a vital but often underrecognized role in the operation of these tissue
banks. Besides interpreting studies that arise from banked samples, pathologists are needed to characterize
tissues for research, to conduct quality assurance programs, to assist with resource allocation decisions, and to
serve an educational role for investigators using the tissues. This article describes these key principles and
illustrates examples where pathologist involvement is crucial to biorepository management. Of overarching
importance, pathologists play a critical role in helping biorepository users understand the principles of specimen
evaluation (histologic and structural composition of tissues, and their limitations) so as to optimize the scientific
benefit of the tissues. In conclusion, greater involvement of pathologists in research tissue banking will enhance
the scientific utility of biorepositories.
Background
The author’s basis of experience was formed as ananatomic/clinical pathologist and as the laboratory
lead (both strategic and managerial) for Pfizer, Inc.’s global
tissue repository. This repository is a collection of >12,000
human and animal tissue samples, obtained from academic
and commercial sources and from a growing number of
clinical trials. Tissues are stored in a variety of fixed and
frozen dispositions to meet various research needs. The tis-
sues from the bank are used to support a wide variety of
discovery and development programs in the company. On a
volume basis, the majority of bank use is human tissue, al-
though preclinical species tissues (especially rat, mouse, and
primate) are of increasing importance. The bank assists in the
acquisition, storage, archiving, and supply of tissue through
a centralized inventory and database and offers tissue sec-
tioning, frozen and paraffin-embedded tissue blocks, histo-
logic quality assurance, and scientific consultations on a
request-driven basis to company investigators. Appropriate
consent and institutional review board approval is in place
for all tissues and contracts, and the use of the tissues is also
governed by Pfizer’s Human Tissue Policy.
This article focuses on best practices pertinent to pathol-
ogists, especially in how they interact with and contribute
to the scientific mission of biorepositories. It is important
to note that these principles apply not just to pharma-
ceutical biobanks but, in large part, to all such banks and
tissue resources supporting research for which pathologists
contribute. Thus, Pfizer, Inc.’s experience could serve as a
useful blueprint for academic, commercial, and other bio-
banks in which maintaining quality assurance for tissues is
crucial. Also, the main focus of this article is on human tis-
sue, although many of the principles would also apply to the
banking and evaluation of animal tissue.
Discussion
To appreciate the roles that pathologists play in research
tissue banking, it is helpful first to consider the ways in
which tissues (both human and preclinical species) support
pharmaceutical and other research. Key examples are given
below.
 Assessment of target expression in normal and disease
tissue: Through the use of immunohistochemistry (IHC),
in situ hybridization (ISH), western blotting, or other pro-
cedures, the expression level of the target, that is, a protein
or other biomolecule with which a drug molecule or bio-
logic substance is intended to interact, can be assessed, and
a judgment can be made about the appropriateness of that
target for the intended research program. A key part of this
assessment is the specificity of a target for the intended
tissue or disease. It is often necessary to study target ex-
pression in a wide variety of tissues, which can be often
facilitated by tissue microarray (TMA) technology (dis-
cussed later).
 Toxicity predictions: Related to the point above, tissue
studies can suggest potential areas of toxicity in either
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humans or preclinical species, by showing high levels of
target expression in organs or tissues different from those
intended. An important subcategory is cross-reactivity as-
sessment of therapeutic antibodies, which is typically done
on frozen tissues so as to best preserve the structural in-
tegrity (and thus antigenicity) of the target protein.
 Biomarker studies: Tissue studies can support or clarify
efforts to develop biomarkers for diagnostic or therapeutic
assessment. Such biomarkers might be measured in the
tissue samples themselves (such as through IHC), or the
tissues might be useful in the assessment or development
of a biomarker measured through other means, such as
serum or urine.
 Field of use claims: Assessment of targets in human tissues
can expand the potential applicability of a given thera-
peutic program, such as by highlighting the expression of a
target in other disease state(s) besides the one originally
considered.
 Preclinical species selection: The similarities and differ-
ences in target expression between human and preclinical
species can assist the selection of the most appropriate
preclinical species in which the human disease can be
modeled or in which preclinical in vivo toleration studies
for a drug molecule under study can be conducted.
 Clinical trials: Tissues obtained before or during a clinical
trial may assist with a number of objectives, including
patient stratification, prognostic assessments, and phar-
macogenomics studies.
Tissue specimen workflow
Understanding the processes by which tissues are pro-
cessed and handled is helpful as a background for a dis-
cussion of pathologist roles. All tissue originates fresh at its
source. From there, tissue may be used in the fresh state,
such as for the establishment of cell cultures. Alternatively,
portions of tissue may be flash-frozen (for maximum long-
term preservation of tissue for molecular studies, including
RNA and metabolomic assessments), embedded in optimal
cutting temperature compound (OCT) for the purposes of
obtaining a histologic frozen section or for IHC, or formalin-
fixed and embedded in paraffin (for various uses including
IHC, ISH, histologic assessment using routine staining). Of
overriding importance are the following principles:
 Standards for the timely collection and processing of tissue
are critically important, for assuring reproducible quality
of tissue and its suitability for later studies. If tissues are
collected across multiple sources for given programs, then
it is important to assure the consistent application of good
standards across the various source sites (this will be fur-
ther discussed subsequently).
 Gross examination of the fresh tissue is important in many
instances, so as to assure that tissue of the right location (ie,
including the disease process) and preservation is taken.
For tumors, this would include sections that avoid necrotic
areas. If available, a pathologist can greatly assist these
determinations. Additionally, tissue must not be removed
in quantities that would hinder the ability to obtain a pri-
mary diagnosis, if the tissue source is a surgical pathology
laboratory. Pathologists can also guide the procurement of
sections that are of the appropriate dimensions to fix or
freeze in a time-efficient manner.
 Preserving tissue in several preservational dispositions
(fixed, flash-frozen, OCT) is optimal, if tissue quantities
and laboratory workflow permit, because it allows the
most flexible set of options for subsequent lab studies.
As often as possible, the tissue repository should endeavor
to review histologic sections for the samples it receives
into the bank, and especially samples it is contemplating
disbursing for research. These slides typically are routine
hematoxylin and eosin (H&E)-stained slides. For most pro-
cesses and workflow paths, this review is feasible. Sections
cut from OCT or paraffin blocks, in particular, are quite
facile, and information gleaned from them readily applies to
additional sections cut from the same block for IHC, ISH,
or other studies. One problematic area for histologic review
arises when a flash-frozen, non-OCT–embedded tissue
specimen arrives from an outside source (typically long term
at 808C or colder) and is intended to be used for research,
typically a digestive assay. Obtaining a histologic section
from such a sample would require embedding in OCT and
sectioning in a cryostat; the latter requires warming to
cryostat temperature, typically *208C. If the research and
investigator needs would render this embedding process
problematic, then the sample may need to be used as is, with
the performance in the assay perhaps serving as a clue to the
tissue’s quality. One way around this challenge is if, at the
source laboratory, the tissue adjacent to the frozen tissue
sample had been previously saved for paraffin embedding.
In this case, review of the paraffin tissue would provide an
acceptable view of the frozen tissue’s histopathology, by
virtue of geographic proximity.
Another point concerns the sections cut from paraffin
blocks and placed on glass slides. Ideally, if these sections are
intended for use in an assay requiring preservation of anti-
genicity (such as IHC), they should be used as soon as pos-
sible after sections are cut, because air oxidation of the slides
may lead to deterioration of the slide’s antigenicity over
time.1,2 The rate at which this occurs is variable and situation
dependent and may be slowed by storing cut slides in an
inert environment such as gaseous N2, or coating them in
paraffin, if they cannot be used right away.2 In some in-
stances, this principle is not fully appreciated, and unstained
slides may be stored under ambient conditions for weeks or
months before using them, which is not completely ideal.
Pathologists can play a role in educating colleagues about the
recommended prompt use of their unstained, previously cut
slide sections.
Principles of specimen evaluation
The key principles of specimen evaluation are given be-
low, which need to be appreciated by pathologists and oth-
ers who manage research tissue repositories.
 Samples received from outside sources may not be of the
type or disease state advertised or may be of poor quality,
that is, necrotic. This occurs more commonly than might be
believed and is usually caused by inadequate tissue pres-
ervation or handling on the source’s end, a mistaken se-
lection of tissue samples from the parent (gross) specimen,
or an error in histologic review. Pathologists, of course, by
virtue of their training, are well positioned to address this
challenge and encourage their investigator colleagues to
submit any new or outside tissue samples for a histologic
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review whenever possible. Examples commonly seen in-
clude pancreas tissue (often necrotic and/or digested by
the time it is procured and stored), tumor samples (which
are often necrotic or nonrepresentative of the whole le-
sion), and dorsal root ganglion tissue (often used in pain
research, these samples may contain only peripheral nerve
or soft tissue without the requisite ganglion cell bodies).
 Certain cell types within a sample, such as epithelial lining,
tumor cells, or an inflammatory component, may need to
be isolated specifically, rather than the whole tissue being
digested in an expression assay. This will depend on the
research questions being addressed. Trogan et al.3 provide
an example with atherosclerotic plaque macrophages,
where this principle was used advantageously. Patholo-
gists play a helpful role in educating their investigator
colleagues about the multicompartmental, 3-dimensional
nature of tissue and how this applies to their endeavors. As
a result, an investigator studying lung cancer will appre-
ciate the sample as a complex mix of tumor cells, inflam-
matory cells, desmoplasia, and normal and dysplastic
epithelial components, with all of these contributing DNA,
RNA, and/or protein signal to assay procedures. Similarly,
an investigator examining a target in ciliated respiratory
epithelium might be guided to enhance their studies by
isolating the epithelium specifically (eg, through laser-
capture microscopy4) rather than submitting the entire
tissue into a digestive procedure. As a corollary, patholo-
gists are important in guiding the optimum performance
and usefulness of laser-capture microscopy, including the
review of H&E sections before the procedure, and the se-
lection of areas to be captured under the microscope.
 Nonneoplastic tissue adjacent to tumor must be regarded
carefully if intended as a fully ‘‘normal’’ control. One rea-
son for this is that molecular changes present in tumor
tissue may also be present as precursor lesions in sur-
rounding tissue. This is especially relevant given that tu-
morigenesis is a multistage process with a high degree of
variability and complexity in the causal genetic lesions.
Often in a single-tissue sample, a progressive spectrum of
neoplastic changes is seen (eg, normal colon, adenomatous
mucosa, in situ disease, and invasive colon carcinoma all in
close proximity), and all will contribute molecular signal in
an assay unless isolated specifically. Of course, the degree
to which this is a concern varies depending on the situation
and the questions being addressed. In some cases, com-
parative studies of tumor and premalignant tissue from the
same patient and organ may be the primary objective.
Another factor relating to tissue adjacent to tumors is that
marked inflammatory infiltrates are often present at the
periphery of some tumors, especially lung cancers and
metastatic tumors in the liver. These infiltrates may dilute
and distort the surrounding nonneoplastic organ paren-
chymal tissue, thereby posing a quality assurance concern.
 Pigments, inflammatory infiltrates, preservation condi-
tions, or other features may affect the intended perfor-
mance of the tissue in an expression assay. Pathologists, of
course, play a crucial role in histologic assessments and
bringing these concerns to light. One common area of
concern is IHC, in which the above adverse features may
hinder the performance or interpretability of the stains.
Sometimes these factors are addressable (eg, excess pig-
ment might be removed or more optimal tissue sections
chosen), and sometimes they are not (eg, a marked pre-
servational deficit in tissue, which obscures the histology
and/or antigenicity).
Because tissue near a tumor or disease process may be
altered morphologically and biochemically as a result of the
proximity to the disease process, truly normal tissue is often
valued as another type of control. There are a variety of
sources for these tissues. Biorepositories in association with
surgical pathology or autopsy services may have access to
properly consented excess tissue (ie, material that would
otherwise be discarded), which is morphologically normal.
Examples include skin and breast tissue that is removed for
cosmetic reasons, and tissue removed as part of the treat-
ment for disease processes, which are distant from and/or
incidental to the tissue(s) of interest. It should be also noted
that several commercial vendors are available, which are
capable of supplying properly consented normal tissues for
research purposes. In such settings, pathologists and others
should ask questions about the original procedure and why
the tissue was made available and should consider any
possible association or effect between that stated history and
the desired ‘‘normal’’ tissue or organ type.
TMA blocks
An important feature of the industrial tissue biorepository
is TMA technology. By virtue of their inclusion of dozens or
hundreds of separate tissue core samples in 1 block, TMA
blocks provide rapid high-throughput screening for studies
involving protein, RNA, or DNA targets, with improved
preservation of tissue resources.5 A traditional TMA is a
paraffin block, though frozen TMAs can be built with OCT
and, though more labor-intensive in their construction, may
be helpful in addressing questions involving labile markers
(eg, messenger RNA and phosphorylated proteins), which
are liable to degrade during paraffin embedding.6 Typically,
TMAs are adaptable to any assay that is routinely done on
tissue sections from regular paraffin or OCT blocks. Multi-
species and multiorgan TMAs may further enhance the
output of information, especially for comparative judgments
involving target expression across various species and organ
types. Importantly, TMAs also provide a high-throughput
substrate of specimens for the analysis of gene expression
and cell signaling pathways that are involved in carcino-
genesis.7
Comprehensive overviews of TMA construction processes
are available.5 The key steps are the selection of ‘‘parent’’
blocks, the coring of these blocks to produce slender tissue
specimens 1–3mm diameter, and the inclusion of dozens to
hundreds of these cores in the new TMA block, along with
clinical/demographic annotation, and an array map (typi-
cally a grid) guiding the user to which specimen is in each
core.
Pathologists play a critical role in the construction, eval-
uation, and use of TMAs:
 Selecting appropriate donor or ‘‘parent’’ blocks for use in
TMA construction, that is, the blocks containing adequate
quantities of the desired tissue or disease type. It is also
necessary to select an appropriate region of the blocks from
which cores can be obtained.
 Configuring TMA parameters appropriately. For example,
too many cores on a slide will yield smaller core areas. This
raises the risk that ‘‘edge artifacts’’ from IHC staining
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(whereby reagent staining is artifactually enhanced along
tissue edges) will obscure useful information.
 Reviewing a histologic slide for TMA blocks, for quality
assurance purposes—making sure that appropriate tissues
are represented in cores, documenting if they are not, and
communicating that information to the user group.
Operating procedures for specimen evaluation
and disbursal
Based on the foregoing principles, the following additional
recommendations are advised for practices within a research
tissue bank in an industrial setting (these would also apply to
a large extent in other settings also):
 Communication between pathologist and repository user
is absolutely essential. Such communication could include
any of the foregoing principles, including tissue quality,
tissue review findings, and appropriateness of a specimen
for the intended research purpose. Because resource allo-
cation decisions may be necessary when competing needs
require the use of scarce or valuable tissues, communica-
tion with users is critical to establish the priorities and
potential benefits of each proposed use.
 The anatomic makeup of the tissue must be considered
against the project goals and methods, with the overriding
concern being the following question: what cells or com-
ponents of the tissue are key to the study or the choice of
controls? The answer will dictate not only the choice of
specimen, but also perhaps the procedure used on the
tissue; for example, after considering the tissue’s histology,
the pathologist and investigator may decide it is necessary
to enrich for the desired cell type by performing micro-
dissection or laser-capture microscopy.
 It is often helpful to supply H&E sections of the tissue
directly to the investigator, with relevant areas of disease
marked, after pathologist review. For oncology specimens,
this may include areas of tumor, premalignant changes,
and benign normal tissue, along with information about
tumor cellularity and percentage of necrosis. Relevant in-
formation can be similarly captured in other disease set-
tings also, for example, areas of inflammation in ulcerative
colitis, or regions of stable and unstable plaque in athero-
sclerosis.
Principles of specimen collection and processing
Specific, reproducible criteria for tissue collection are quite
important for quality assurance purposes, and these should
be standardized as much as possible across the multiple
collection sites that the tissue repository uses as its sources.
Clear, practical procedures and recommendations are nee-
ded, and good communication is essential. Pathologists
managing tissue repositories, and also the bank’s users,
should understand collection practices and how they might
impact their studies and the quality of received tissue. Pa-
thologists should of course also be familiar with biomarkers
for specimen quality (eg, RNA integrity number8) and be
ready to use that information in specimen selections and in
correlating with histologic findings and/or assay results.
Good specimen handling and preservation practices are
important for their influence on tissue quality in bior-
epository management, just as they are in other laboratory
settings such as surgical pathology. Such practices have been
thoroughly described.9 Numerous lines of evidence support
the influence of collection practices on the quality of results
derived from tissues.9,10 There is a recent trend within some
biobanking endeavors to attempt to collect very precise ac-
quisition information, such as the exact times the specimen
spends in various parts of the acquisition/processing path-
way. The extent to which this is feasible will of course vary
depending on the individual laboratory. However, as very
basic minimums, the following recommendations are ad-
vised: Surgical samples should be processed (either formalin-
fixed or frozen) as soon as possible after removal from the
patient, but no later than half an hour. Autopsy specimens
should preferably be processed within 4 h of postmortem
time, and no later than 8 h. Specimens in formalin should be
processed within 24 h to avoid overfixation (which could
compromise the antigenicity of proteins). Biorepositories,
especially those in close proximity to surgical pathology
services, may consider coordinating their practices with a
tracking sheet or documentation system, which specifies the
time of procurement in the operating room and the arrival
time in the pathology laboratory or other location where the
specimen is fixed and/or frozen. Such a tracking system,
especially if implemented in ‘‘real time’’ (ie, specimen
transport as quickly as possible), may increase the yield of
research tissue from large surgical specimens, which, absent
the need for frozen sections, might not arrive in the pathol-
ogy laboratory quickly enough to be useful for biobanking.
Such a collection system obviously requires good chain-of-
custody measures and a good cooperation and communica-
tion between the pathology laboratory and surgical areas.
Biorepositories that are distant from the sites of collection
(this includes most if not all pharmaceutical human tissue
banks) will need to emphasize the importance of good col-
lection practices to the sites, perhaps implementing a track-
ing system similar to that described above, which should
yield transparent quality control data related to timely
collection.
When reviewing samples, pathologists should be alert for
preservational problems reflected in the histology and be
prepared to alert the processing laboratory and make chan-
ges in the process flow based on such findings. Although
some types of human tissues will be primarily available in
quantity through autopsy procurement (eg, brain and car-
diac tissue), pathologists and repository users should keep
in mind the limitations of such tissues for work with sensi-
tive macromolecules, because postmortem times are rarely
<2–4 h. Pathologists should also consider the availability of
specialized fixatives (eg, Carnoy’s, methacarn, acetone, and
HOPE fixative) for specific research objectives.9 The reader is
referred to formal best practice documents published by
well-known biobanking organizations for additional details
on quality assurance and specimen storage and transport, as
well as other topics whose in-depth discussion is beyond the
scope of this article, such as informed consent, informatics
systems, and biosafety practices.11,12
Still another area of growing recognition is the presence of
preacquisition variables, such as patient medications, blood
and fluid administration, anesthesia, blood pressure varia-
tions, and clamp time, which likely have some influence on
gene expression and proteomic profiles in some cases and
thus potentially on research findings.10,13 It is not likely that
biorepositories will be able to control for these factors or
200 MCDONALD
even document them accurately. However, this is an un-
derstudied area that will probably elicit more attention in the
future and so should be followed by pathologists and others
involved in biorepository management.
Conclusion
Research tissue banking is important in promoting a va-
riety of scientific objectives, including discovery and devel-
opment programs in the pharmaceutical industry.14 Full use
of this resource requires good histopathological science and
close cooperation and good communication with investiga-
tors. Pathologists are well positioned to provide scientific
leadership, especially with respect to specimen quality and
evaluation, and thereby maximize the scientific benefit of
tissue repositories.
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